Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of infliximab trough levels from interval serum levels in Crohn's disease maintenance therapy
NL-OMON41068Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Amsterdam University Medical Center. Primary endpoint: Serum infliximab level. Started Jul 2014; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON41068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41068.